L309-0095 Screening compound: 4-[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]-6-{[3-methyl-4-(3-methylphenyl)piperazin-1-yl]sulfonyl}-3,4-dihydro-2H-1,4-benzoxazin-3-one

L309-0095 Screening compound: 4-[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]-6-{[3-methyl-4-(3-methylphenyl)piperazin-1-yl]sulfonyl}-3,4-dihydro-2H-1,4-benzoxazin-3-one
L309-0095 Screening compound: 4-[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]-6-{[3-methyl-4-(3-methylphenyl)piperazin-1-yl]sulfonyl}-3,4-dihydro-2H-1,4-benzoxazin-3-one alternative view

Chemical Structure Depiction of ChemDiv screening compound L309-0095
4-[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]-6-{[3-methyl-4-(3-methylphenyl)piperazin-1-yl]sulfonyl}-3,4-dihydro-2H-1,4-benzoxazin-3-one

Available from 1 mg

Formats:

  • Glass Vials (4ml Glass Vials VWR #97047-678)
  • 96-tube racks (Matrix #4247 96-well 1.4ml sealed with capmats, empty cols 1 & 12, 100uL of 10mM)

Shiptime: 1 week worldwide delivery in most cases

Compound Identifiers

ChemDiv Compound ID

L309-0095

Molecular Formula

C24H27N5O5S (C24 H27 N5 O5 S)

Compound Name

4-[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]-6-{[3-methyl-4-(3-methylphenyl)piperazin-1-yl]sulfonyl}-3,4-dihydro-2H-1,4-benzoxazin-3-one

IUPAC name

4-[(5-methyl-124-oxadiazol-3-yl)methyl]-6-{[3-methyl-4-(3-methylphenyl)piperazin-1-yl]sulfonyl}-34-dihydro-2H-14-benzoxazin-3-one

SMILES

CC(CN(CC1)S(c(cc2)cc(N3Cc4noc(C)n4)c2OCC3=O)(=O)=O)N1c1cc(C)ccc1

InChI

InChI=1S/C24H27N5O5S/c1-16-5-4-6-19(11-16)28-10-9-27(13-17(28)2)35(31,32)20-7-8-22-21(12-20)29(24(30)15-33-22)14-23-25-18(3)34-26-23/h4-8,11-12,17H,9-10,13-15H2,1-3H3/t17-/m0/s1

InChI Key

FQSZIKPWHYBGGA-KRWDZBQOSA-N

MDL Number (MFCD)

MFCD27243949

Chemical and Physical Properties

Saltdata

n/a

Molecular Weight

497.58

Hydrogen Bond Acceptors Count

11.00

Hydrogen Bond Donors Count

0.00

Rotatable Bond Count

5.00

Number of Nitrogen and Oxygen Atoms

10

Partition Coefficient, logP

3.019

Distribution Coefficient, logD

3.019

Water Solubility, LogSw

-3.35

Polar Surface Area

90.425

Acid Dissociation Constant (pKa)

20.50

Base Dissociation Constant (pKb)

2.75

Number of Chiral Centers

1.00

Percent sp3 carbon bonding

37.50

L309-0095 in Drug Discovery

Included in Screening Libraries

3D-Pharmacophore Based Diversity Library (49813 compounds)

Protein Kinases Inhibitors Library (36801 compounds)

Included in 1.7M Stock Database

Therapeutical areas:
  • Cancer
  • Digestive system
  • Respiratory tract
  • Otorhinolaryngologic
  • Nervous system
  • Hemic and lymphatic
  • Cardiovascular
Targets:
  • Kinases

References: we are preparing a list of scientific research reports with L309-0095 chemical compound. It will be published here after verification.

Frequently Asked Questions

How to purchase chemical compound L309-0095?
Check Price and Availability of L309-0095, then you can add required amount to the Shopping Cart. In the Shopping Cart you can again refine your selection. Once you are sure that it’s exactly what you want you can move forward with the Checkout (to pay online by credit card, or via PayPal), or Request a Quote.
What is the minimum amount of L309-0095 you sell to drug discovery company or institution?
Available from 1 mg in Glass Vials or 96-tube racks.
Delivery options for L309-0095
ChemDiv sends parcels with Express services (UPS, WC).
  • 1–2 days for small orders
  • 2–4 weeks for large selections
Delivery formats for L309-0095
  • 0.5–50 mg of dry powder sample in single glass vials, custom vials
  • DMSO solutions frozen 10μl–250μl@10mM (96 and 384 format)

Custom synthesis of L309-0095 available by request